Tykerb and Doxil drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tykerb (lapatinib ditosylate) and Doxil (doxorubicin hydrochloride). Common drug interactions include metastases to central nervous system among females and gastrointestinal haemorrhage among males.

The phase IV clinical study analyzes what interactions people have when they take Tykerb and Doxil. It is created by eHealthMe based on reports of 29 people who take the same drugs from the FDA, and is updated regularly.

What is Tykerb?

Tykerb has active ingredients of lapatinib ditosylate. It is often used in breast cancer. eHealthMe is studying from 12,231 Tykerb users. Check the latest studies of Tykerb.

What is Doxil?

Doxil has active ingredients of doxorubicin hydrochloride. It is often used in ovarian cancer. eHealthMe is studying from 10,479 Doxil users. Check the latest studies of Doxil.



On Aug, 02, 2026

29 people who take Tykerb and Doxil together, and have interactions are studied.

Tykerb and Doxil drug interactions.

What are the common drug interactions of Tykerb and Doxil, by gender? *:

female:

  1. Metastases to central nervous system (cancer spreads to central nervous system)
  2. Pain
  3. Abdominal pain
  4. Hypoaesthesia (reduced sense of touch or sensation)
  5. Metastases to liver (cancer spreads to liver)
  6. Chest pain
  7. Fatigue (feeling of tiredness)
  8. Metastases to lymph nodes (cancer spreads to lymph node)
  9. Pleural effusion (water on the lungs)
  10. Anhedonia (inability to experience pleasure from activities usually found enjoyable)

male:

  1. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  2. Abdominal pain
  3. Arthralgia (joint pain)
  4. Arthritis (form of joint disorder that involves inflammation of one or more joints)
  5. Ascites (accumulation of fluid in the abdominal cavity)
  6. Back pain
  7. Blood glucose decreased
  8. Bone pain
  9. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  10. Cardiomegaly (increased size of heart than normal)

What are the common drug interactions of Tykerb and Doxil, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Constipation
  2. Diarrhoea
  3. Gait disturbance
  4. Hypoaesthesia (reduced sense of touch or sensation)
  5. Nausea (feeling of having an urge to vomit)
  6. Pain
  7. Rash
  8. Upper respiratory tract infection

50-59:

  1. Cardiomegaly (increased size of heart than normal)
  2. Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe)
  3. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body)
  4. Dermal cyst
  5. Disability
  6. Dizziness
  7. Dyspnoea (difficult or laboured respiration)
  8. Escherichia sepsis (bacterial infection by escherichia coli)
  9. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  10. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)

60+:

  1. Metastases to lymph nodes (cancer spreads to lymph node)
  2. Pleural effusion (water on the lungs)
  3. Skin fissures (a crack in the skin)
  4. Streptococcal sepsis (whole body inflammation by streptococcal)
  5. Nail bed inflammation (infection of nail bed)
  6. Nausea (feeling of having an urge to vomit)
  7. Back pain
  8. Metastases to central nervous system (cancer spreads to central nervous system)
  9. Vomiting
  10. Sepsis (a severe blood infection that can lead to organ failure and death)

What are the existing conditions these people have? *

  1. Metastases To Bone (cancer spreads to bone): 10 people, 34.48%
  2. Dyspnea (difficult or laboured breathing): 5 people, 17.24%
  3. Cough: 5 people, 17.24%
  4. Breast Cancer Metastatic: 5 people, 17.24%
  5. Gastrointestinal Disorder (functional problems of gastrointestinal tract): 4 people, 13.79%
  6. Eczema (patches of skin become rough and inflamed, with itching and bleeding blisters): 4 people, 13.79%
  7. Skin Fissures (a crack in the skin): 3 people, 10.34%
  8. Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 3 people, 10.34%
  9. Streptococcal Sepsis (whole body inflammation by streptococcal): 2 people, 6.90%

* Approximation only. Some reports may have incomplete information.

Do you take Tykerb and Doxil?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tykerb and Doxil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tykerb:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Doxil:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tykerb and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Doxil and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lapatinib ditosylate and doxorubicin hydrochloride (the active ingredients of Tykerb and Doxil, respectively), and Tykerb and Doxil (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: